公开(公告)号：US12275719B2

公开(公告)日：2025-04-15

申请号：US17439845

申请日：2020-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  David S. Yoon ,  Wei Wang ,  Jianxin Feng ,  Bruce A. Ellsworth ,  Alicia Regueiro-Ren

IPC: C07H17/02 ,  C07D405/14 ,  C07D417/14 ,  C07H19/056

Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US11787779B2

公开(公告)日：2023-10-17

申请号：US17242428

申请日：2021-04-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  Michael G. Yang ,  Zili Xiao ,  Ling Chen ,  Ryan M. Moslin ,  John S. Tokarski ,  David S. Weinstein ,  Stephen T. Wrobleski

IPC: C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/6558 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

CPC classification number: C07D401/14 ,  A61K31/501 ,  A61P29/00 ,  A61P37/00 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07F9/65583

Abstract: Compounds having the following formula I:




or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20230322770A1

公开(公告)日：2023-10-12

申请号：US18042018

申请日：2021-08-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  Alicia Regueiro-Ren

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formulas (I) and (II): or a salt thereof, wherein X, Y, Q1, Q2, G, R1, and R3 are defined N herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing fibrotic diseases.

公开(公告)号：US11168079B2

公开(公告)日：2021-11-09

申请号：US16759660

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joseph E. Carpenter ,  Matthias Broekema ,  Jianxin Feng ,  Chunjian Liu ,  Wei Wang ,  Ying Wang

IPC: C07D401/14 ,  A61K31/4545 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20210253554A1

公开(公告)日：2021-08-19

申请号：US17242428

申请日：2021-04-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  Michael G. Yang ,  Zili Xiao ,  Ling Chen ,  Ryan M. Moslin ,  John S. Tokarski ,  David S. Weinstein ,  Stephen T. Wrobleski

IPC: C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/6558 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US11021462B2

公开(公告)日：2021-06-01

申请号：US16195951

申请日：2018-11-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  Michael G. Yang ,  Zili Xiao ,  Ling Chen ,  Ryan M. Moslin ,  John S. Tokarski ,  David S. Weinstein ,  Stephen T. Wrobleski

IPC: A61K31/395 ,  C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/6558 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20200071315A1

公开(公告)日：2020-03-05

申请号：US16687279

申请日：2019-11-18

Applicant: Bristol-Myers Squibb Company

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Yanlei ,  Qingjie Liu

IPC: C07D417/14 ,  C07B59/00 ,  C07D417/12 ,  C07D413/12 ,  C07D403/14 ,  C07D237/24 ,  C07D401/12 ,  C07D413/14 ,  C07D401/14 ,  C07D403/12

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20180265504A1

公开(公告)日：2018-09-20

申请号：US15979770

申请日：2018-05-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang ,  Qingjie Liu

IPC: C07D417/14 ,  C07B59/00 ,  C07D417/12 ,  C07D413/12 ,  C07D403/12 ,  C07D237/24 ,  C07D401/12 ,  C07D413/14 ,  C07D401/14 ,  C07D403/14

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US10000480B2

公开(公告)日：2018-06-19

申请号：US15289437

申请日：2016-10-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Stephen T. Wrobleski ,  John S. Tokarski ,  Amit Kumar ,  Douglas G. Batt ,  Shuqun Lin ,  Chunjian Liu ,  Steven H. Spergel ,  Yanlei Zhang ,  Qingjie Liu

IPC: C07D417/14 ,  C07D403/12 ,  C07D401/14 ,  C07D413/14 ,  C07D401/12 ,  C07D237/24 ,  C07D403/14 ,  C07D413/12 ,  C07D417/12 ,  C07B59/00

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.